Search
Selonsertib
go.drugbank.com/drugs/DB14916InvestigationalSelonsertib is under investigation in clinical trial NCT03053050 (Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis).
Synonyms: 5-(4-Cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methyl-N-{6-[4-(propan-2-yl)-4H-1,2,4-triazol-3-yl]pyridin-2-yl}benzamide, 5-(4-Cyclopropyl-1H-imidazol-l-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamideFirsocostat
go.drugbank.com/drugs/DB16166InvestigationalFirsocostat is under investigation in clinical trial NCT02781584 (Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)).
Remogliflozin etabonate
go.drugbank.com/drugs/DB12935InvestigationalRemogliflozin etabonate has been used in trials studying the treatment and basic science of Type 2 Diabetes Mellitus and Diabetes Mellitus, Type 2.
Pemlimogene merolisbac
go.drugbank.com/drugs/DB16286InvestigationalPemlimogene merolisbac is under investigation in clinical trial NCT03371381 (An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab
Synonyms: Recombinant live-attenuated double-deleted (ladd) strain of listeria monocytogenes (lm .delta.acta/.delta.inlb) expressing a fusion protein comprising the n-terminal 100 amino acids of the lm acta proteinSNS01-T
go.drugbank.com/drugs/DB17302InvestigationalIt is composed of three components: a B cell-specific plasmid expressing eIF5AK50R; an siRNA that targets the native eIF5A that promotes growth/anti-apoptosis of cancer cells; and polyethylenimine.
LV305
go.drugbank.com/drugs/DB17288InvestigationalLV305 is a lentiviral vector encoding NY-ESO-1 gene. LV305 is an active component of CMB305 along with [G305].[L47346]
Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences)
go.drugbank.com/drugs/DB15863ExperimentalThis vaccine specifically was developed in collaboration with the Chinese Academy of Medical Sciences, West China Second University Hospital, and Yunan Center for Disease Control and Prevention. … As of June, 2020, safety and Immunogenicity trials are currently underway for this vaccine (NCT04470609 & NCT04412538).